Cover Image
Market Research Report

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 368720
Published Content info 87 Pages
Delivery time: 1-2 business days
Price
Back to Top
Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2018
Published: October 16, 2018 Content info: 87 Pages
Description

Summary:

Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization.

Human Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 28 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 2 and 12 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health, Gastrointestinal and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer, Anal Cancer, Anal Dysplasia, Glioblastoma Multiforme (GBM), Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Oropharyngeal Cancer, Penile Cancer, Vaginal Cancer and Vulvar Cancer.

The latest report Human Papillomavirus Protein E6 - Pipeline Review, H2 2018, outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
  • The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1733TDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Human Papillomavirus Protein E6 (E6) - Overview
    • Human Papillomavirus Protein E6 (E6) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development
    • Abion Inc
    • BioNTech AG
    • Cancer Research Technology Ltd
    • Etubics Corp
    • Genexine Inc
    • Hookipa Biotech AG
    • Immunomic Therapeutics Inc
    • Inovio Pharmaceuticals Inc
    • MedImmune LLC
    • Rottapharm Biotech Srl
    • Selecta Biosciences Inc
    • Touchlight Genetics Ltd
    • Transgene SA
  • Human Papillomavirus Protein E6 (E6) - Drug Profiles
    • ABN-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies to Inhibit E6 for HPV Associated Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bizalimogene ralaplasmid + mavilimogene ralaplasmid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BVAC-C - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETBX-041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GX-188E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus [serotype 16] vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-3106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITI-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-0457 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Target E6 and E7 for Human Papillomavirus (HPV) Associated Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PVX-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TA-CIN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tipapkinogene sovacivec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Tricurin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for HPV Associated Cervical Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vvax-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Human Papillomavirus Protein E6 (E6) - Dormant Products
  • Human Papillomavirus Protein E6 (E6) - Discontinued Products
  • Human Papillomavirus Protein E6 (E6) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 02, 2018: Major Cancer Journal highlights data from An Inovio-Sponsored trial in which a patient achieved full remission after dosing with DNA immunotherapy and checkpoint inhibitor
      • Sep 21, 2018: DNA vaccine leads to immune responses in HPV-related head and neck cancer
      • May 21, 2018: Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV - The No. 1 Sexually Transmitted Disease
      • May 15, 2018: New Insights into Hookipa's TheraT Replicating Viral Vector Platform Published in Immunity
      • Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
      • Nov 29, 2017: Inovio's Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
      • Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3112
      • Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference
      • Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
      • Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer
      • Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
      • May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
      • Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
      • Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech
      • Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indication, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Companies, H2 2018 (Contd..2), H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by Abion Inc, H2 2018
  • Pipeline by BioNTech AG, H2 2018
  • Pipeline by Cancer Research Technology Ltd, H2 2018
  • Pipeline by Etubics Corp, H2 2018
  • Pipeline by Genexine Inc, H2 2018
  • Pipeline by Hookipa Biotech AG, H2 2018
  • Pipeline by Immunomic Therapeutics Inc, H2 2018
  • Pipeline by Inovio Pharmaceuticals Inc, H2 2018
  • Pipeline by MedImmune LLC, H2 2018
  • Pipeline by Rottapharm Biotech Srl, H2 2018
  • Pipeline by Selecta Biosciences Inc, H2 2018
  • Pipeline by Touchlight Genetics Ltd, H2 2018
  • Pipeline by Transgene SA, H2 2018
  • Dormant Projects, H2 2018
  • Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
Back to Top